Star Pharma & Medical General Store

Pressurized metered dose inhalers (pMDIs), first introduced in 1956, are considered an effective delivery method for many important drugs used to treat asthma and chronic obstructive pulmonary disease (COPD). Due to the advantages that it offers, including reliability, accurate dosing, convenience and low cost, pMDIs remain the most popular and widely used delivery device in the world.
However, one of the most difficult challenges for patients using a pMDI is keeping track of the number of doses taken and when to replace the pMDI. Also, patients rely on inaccurate methods of determining whether a pMDI canister is depleted, such as by shaking the inhaler or estimating the weight of the canister. Thus, patients are at a risk of taking sub-therapeutic doses; also, they may either discard the inhaler before it has been fully used or continue to use the inhaler beyond its labelled number of doses.
As an ongoing commitment towards respiratory medicine, Cipla introduces the US FDA approved dose counter in SEROFLO Inhaler, that will provide reassurance and confidence that the medication can be relied upon, as well as reduce the risks of taking sub-therapeutic doses by using the inhaler past the number of doses guaranteed on the product label. before it has been fully used or continue to use the inhaler beyond its labelled number of doses.
As an ongoing commitment towards respiratory medicine, Cipla introduces the US FDA approved dose counter in SEROFLO Inhaler, that will provide reassurance and confidence that the medication can be relied upon, as well as reduce the risks of taking sub-therapeutic doses by using the inhaler past the number of doses guaranteed on the product label.